Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "AstraZeneca"

255 News Found

Piramal Pharma Solutions appoints Herve Berdou as COO
People | June 23, 2022

Piramal Pharma Solutions appoints Herve Berdou as COO

Brings 25 years of global operations and supply chain experience to Piramal


Innate Pharma announces IPH5201 phase 2 study in lung cancer
News | June 04, 2022

Innate Pharma announces IPH5201 phase 2 study in lung cancer

Innate to receive $5M milestone payment from AstraZeneca


Vaxzevria approved in the EU as third dose booster against Covid-19
Drug Approval | May 23, 2022

Vaxzevria approved in the EU as third dose booster against Covid-19

Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine


Dapagliflozin met primary endpoint in DELIVER Phase III trial
Biotech | May 23, 2022

Dapagliflozin met primary endpoint in DELIVER Phase III trial

Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction


Akston Biosciences doses first participants in Phase II clinical trial for Covid-19 booster
Biotech | May 13, 2022

Akston Biosciences doses first participants in Phase II clinical trial for Covid-19 booster

AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022


New nirsevimab data analyses reinforce efficacy against RSV
Biotech | May 11, 2022

New nirsevimab data analyses reinforce efficacy against RSV

Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose


Indian Pharma Market slips for third month in a row: Anand Rathi
News | May 10, 2022

Indian Pharma Market slips for third month in a row: Anand Rathi

According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Biotech | April 27, 2022

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers


Sygnature Discovery acquires Peak Proteins
Biotech | April 26, 2022

Sygnature Discovery acquires Peak Proteins

Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes